Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 33 Show results per page	View Search Criteria \| Help With Results


1.		Zevalin and BEAM High-Dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin’s Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 to 65				Other				Sor451107ctil NCT00463463


2.		Zevalin-Beam for Aggressive Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 65				Other				SHEBA-07-4466-AN-CTIL NCT00491491

Last Modified: 8/8/2007 First Published: 3/1/2001


3.		Phase I/II Study of Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab With and Without Filgrastim (G-CSF) and Interleukin-11 in Patients With Relapsed or Refractory Low-Grade or Follicular CD20+ Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				MAYO-MC998C NCI-312, NCT00012298


4.		Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 70				Other				ID01-233 NCT00048737

Last Modified: 11/22/2006 First Published: 11/3/2006


5.		Phase I/II Study of Rituximab, Fludarabine, and Cyclophosphamide Followed by Radioimmunotherapy Comprising Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Relapsed Indolent, Mantle Cell, or Transformed CD20-Positive B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				51 to 75				Other				KRDI-TUM-R-F-015-V-0030-I EU-20633, NCT00397800


6.		High Dose, Absorbed Dose Adjusted 90Y-Ibritumomab With PBSC Support in B-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				6th radioimmunotherapy prot. EudraCT number: 2007-002762-35, NCT00761384


7.		Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 65				Other, Pharmaceutical / Industry				ZEV0701 NCT00807196

Last Modified: 1/10/2009 First Published: 9/24/2003


8.		Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone and Radiotherapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Aggressive High-Risk Stage I or IE or Non-Bulky Stage II or IIE CD20-Positive Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				NCI				SWOG-S0313 S0313, NCT00070018

Last Modified: 11/7/2008 First Published: 11/20/2003


9.		Phase II Study of Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				BIDMC-2003P-000182 NCT00073957

Last Modified: 7/27/2007 First Published: 4/7/2005


10.		Phase II Study of Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan as First-Line Treatment in Patients With Indolent Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				Other, Pharmaceutical / Industry				BIDMC-2004P-000044 NCT00110149

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute